Preclinical in vitro and xenograft study proposing a mechanism by which an existing drug may enhance chemotherapy, without clinical efficacy data or human evidence.
A narrative review synthesizing current evidence on immunotherapy in advanced biliary tract cancer, highlighting established standards (TOPAZ-1, KEYNOTE-966), emerging biomarkers, and investigational approaches rather than reporting original trial results.
A narrative review synthesizing clinical trial evidence, regulatory approvals, and translational findings to propose a strategic framework for advancing Lu-177 radiopharmaceutical therapy, rather than reporting a primary empirical result.
A structured narrative review synthesizing pathophysiological mechanisms, drug hepatotoxicity profiles, and a proposed clinical management framework for treatment-related liver injury in HBV-associated HCC, intended to guide clinical decision-making.
A sound methodological approach (PBPK-VBE modeling) applied to a regulatory question, but based on simulation and in vitro data without in vivo clinical confirmation across the lower dose range, making it supportive rather than definitive evidence.
A narrative review synthesizing preclinical structure-activity data and early-stage clinical experience to propose design principles for CXCR4 radiotheranostics; no new primary data or comparative efficacy evidence is reported.
Integrative multi-omics study with confirmatory survival analyses across multiple cohorts and mechanistic validation in TNBC cells and xenografts, but lacks clinical trial evidence and therapeutic efficacy data in vivo.
A policy brief presenting expert recommendations for managing infections in cancer patients amid antimicrobial resistance in sub-Saharan Africa, informed by institutional microbiological data but not a primary research study.